Medtronic plc has released its financial results for the fiscal year ended April 25, 2025. The company reported GAAP net income attributable to Medtronic of $4.662 billion, an increase from $3.676 billion in the previous fiscal year. The GAAP diluted earnings per share $(EPS)$ rose to $3.61 from $2.76. The effective tax rate also decreased to 16.6% from 23.4%. Non-GAAP adjustments included an increase in amortization of intangible assets to $1.807 billion, contributing to a non-GAAP net income of $7.079 billion, up from $5.49 billion in the prior year. Medtronic's Surgical & Endoscopy division reported flat net sales for fiscal year 2025 compared to 2024, impacted by declines in Stapling and Endoscopy segments. However, growth in Advanced Energy, driven by the continued adoption of LigaSure vessel sealing technology, partially offset these declines. Similarly, the Acute Care & Monitoring division's net sales remained flat year-over-year, with growth in the BIS Advance monitoring system offset by declines in Medtronic Care Management Services. Looking forward, Medtronic anticipates that its Medical Surgical segment could be influenced by the acceptance and growth of Open-to-MIS (minimally invasive surgery).